Published in Agents Actions on January 01, 1986
Histocompatibility matching. VI. Miniaturization of the mixed leukocyte culture test: a preliminary report. Transplantation (1971) 5.43
Dissociation of hemolytic and lymphocyte-transforming activities of streptolysin S preparations. J Exp Med (1969) 1.45
Purification and properties of an extracellular blastogen produced by group A streptococci. J Exp Med (1979) 1.25
Functional and immunological characterization of the stimulation of human lymphocytes with a mitogen from group A streptococci (SM). Cell Immunol (1982) 0.92
Induction of Ia-like antigens by a group A streptococcal product with mitogenic activity. Transplant Proc (1981) 0.87
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol (2000) 4.23
Enhancement of sheep red blood cell human lymphocyte rosette formation by the sulfhydryl compound 2-amino ethylisothiouronium bromide. Clin Immunol Immunopathol (1975) 3.11
Isolation of human T and B lymphocytes by rosette formation with 2-aminoethylisothiquronium bromide (AET) -treated sheep red blood cells with monkey red blood cells. J Immunol Methods (1976) 2.30
Expression of Ia-like antigens in normal human nonlymphoid tissues. Transplantation (1981) 2.29
Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest (1991) 2.08
Studies on the control of antibody synthesis. 3. Changes in heterogeneity of antibody affinity during the course of the immune response. Immunology (1973) 2.07
Effect of prostaglandin E 1 on adjuvant arthritis. Nature (1971) 2.02
Mechanisms underlying binding of immune complexes to macrophages. J Exp Med (1971) 2.00
Predicting patient satisfaction from physicians' nonverbal communication skills. Med Care (1980) 1.95
Antigen-processing machinery breakdown and tumor growth. Immunol Today (2000) 1.82
Structural studies of murine I-E and human DR antigens. Mol Immunol (1979) 1.79
Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol (2000) 1.77
Studies on the lymphocyte 5'-nucleotidase in chronic lymphocytic leukemia, infectious mononucleosis, normal subpopulations, and phytohemagglutinin-stimulated cells. Cancer Res (1974) 1.74
Murine Ia and human DR antigens: homology of amino-terminal sequences. Proc Natl Acad Sci U S A (1978) 1.70
Characterization of the WIDR: a human colon carcinoma cell line. In Vitro (1979) 1.69
Serum HLA class I antigens: markers and modulators of an immune response? Immunol Today (1995) 1.69
Expression of the high molecular weight melanoma-associated antigen by pericytes during angiogenesis in tumors and in healing wounds. Am J Pathol (1990) 1.66
Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet (2005) 1.63
Structural polymorphism of human DR antigens. Nature (1979) 1.63
DR (Ia-like) antigens on human melanoma cells. Serological detection and immunochemical characterization. J Exp Med (1979) 1.63
Gouty arthritis following gunshot wound: a case report. N Y State J Med (1992) 1.59
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene (2008) 1.59
A rapid method for direct HL-A typing of cultured lymphoid cells. J Immunol (1971) 1.55
Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer (1981) 1.55
Characterization of Ia antigens in mouse serum. J Immunol (1976) 1.51
HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today (1999) 1.47
Rheumatic fever in children. Am Heart J (1980) 1.47
Cardiopulmonary resuscitation in patients with the acquired immunodeficiency syndrome. A prospective study. Arch Intern Med (1988) 1.46
Re.: Purification of IgG monoclonal antibody by caprylic acid precipitation. J Immunol Methods (1983) 1.45
Development and characterization of human constitutive proteasome and immunoproteasome subunit-specific monoclonal antibodies. Tissue Antigens (2005) 1.45
Dissociation of hemolytic and lymphocyte-transforming activities of streptolysin S preparations. J Exp Med (1969) 1.45
Differential expression of intercellular adhesion molecule 1 in primary and metastatic melanoma lesions. Cancer Res (1990) 1.43
TAP off--tumors on. Immunol Today (1997) 1.43
Thromboxane A2 regulates protein synthesis of cultured human mesangial cells. J Lab Clin Med (1992) 1.43
Risk of rheumatic-fever recurrences after streptococcal infections. Prospective study of clinical and social factors. N Engl J Med (1971) 1.42
Clinical significance of alpha(v)beta3 integrin and intercellular adhesion molecule-1 expression in cutaneous malignant melanoma lesions. Cancer Res (1997) 1.42
Competence of thoracic duct cells in the transfer of adjuvant disease and delayed hypersensitivity. Evidence that mycobacterial components are required for the successful transfer of the disease. Cell Immunol (1972) 1.42
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression. Am J Pathol (1999) 1.41
Natural history of rheumatic aortic regurgitation. Criteria predictive of death, congestive heart failure, and angina in young patients. Circulation (1971) 1.41
Living wills. Lancet (1994) 1.39
Purification of immunologically functional subsets of human Ia-like antigens on a monoclonal antibody (Q5/13) immunoadsorbent. J Immunol (1980) 1.38
Endoplasmic reticulum chaperone-specific monoclonal antibodies for flow cytometry and immunohistochemical staining. Tissue Antigens (2003) 1.36
Purification of murine IgG monoclonal antibodies by precipitation with caprylic acid: comparison with other methods of purification. Hybridoma (1989) 1.32
Human DR (Ia-like) antigens: biological and molecular profile. Contemp Top Mol Immunol (1978) 1.31
Cellular immune response to human sarcomas: cytotoxic T cell clones reactive with autologous sarcomas. I. Development, phenotype, and specificity. J Immunol (1986) 1.30
MHC antigens in human melanomas. Semin Cancer Biol (1991) 1.28
Distribution of human Class I (HLA-A,B,C) histocompatibility antigens in normal and malignant tissues of nonlymphoid origin. Cancer Res (1984) 1.26
Where have all the T cells gone? Mechanisms of immune evasion by tumors. Immunol Today (1999) 1.26
Adenosine deaminase activity in chronic lymphocytic leukemia. Relationship to B- and T-cell subpopulations. J Clin Invest (1976) 1.25
Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res (2001) 1.25
Heterogeneity in the expression of HLA and tumor-associated antigens by surgically removed and cultured breast carcinoma cells. Cancer Res (1983) 1.25
Human high molecular weight melanoma-associated antigen (HMW-MAA) mimicry by mouse anti-idiotypic monoclonal antibody MK2-23: induction of humoral anti-HMW-MAA immunity and prolongation of survival in patients with stage IV melanoma. Proc Natl Acad Sci U S A (1992) 1.24
Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res (1994) 1.24
Ultrastructural, immunologic, and functional studies on Sézary cells: a neoplastic variant of thymus-derived (T) lymphocytes. Proc Natl Acad Sci U S A (1974) 1.24
Regulatory role of a monomorphic determinant of HLA Class I antigens in T cell proliferation. J Immunol (1985) 1.23
Selective histocompatibility leukocyte antigen (HLA)-A2 loss caused by aberrant pre-mRNA splicing in 624MEL28 melanoma cells. J Exp Med (1999) 1.22
Changes in Ia-like antigen expression on malignant human cells. Immunogenetics (1981) 1.22
Serologic and immunochemical characterization of the specificity of four monoclonal antibodies to distinct antigenic determinants expressed on subpopulations of human Ia-like antigens. J Immunol (1981) 1.21
HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res (1998) 1.21
Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Invest (1991) 1.21
Infections associated with Hickman catheters in patients with acquired immunodeficiency syndrome. Am J Med (1989) 1.20
Evaluation of C3 receptors on lymphoid cells with different complement sources. J Immunol (1974) 1.19
Lymphocyte mitogens of staphylococcal origin. Ann N Y Acad Sci (1974) 1.19
Rheumatic fever in siblings. Similarity of its clinical manifestations. N Engl J Med (1968) 1.18
Characterization of a monoclonal antibody-defined human melanoma-associated antigen susceptible to induction by immune interferon. J Immunol (1987) 1.18
beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest (1998) 1.17
Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma. Cancer Res (1988) 1.17
Differential role of distinct determinants of intercellular adhesion molecule-1 in immunologic phenomena. J Immunol (1989) 1.17
Stimulation of human T lymphocytes by PHA-activated autologous T lymphocytes: analysis of the role of Ia-like antigens with monoclonal antibodies. Immunogenetics (1981) 1.16
CSPG4 in cancer: multiple roles. Curr Mol Med (2010) 1.15
Prostaglandin E 1 as a regulator of lymphocyte function. Selective action on B lymphocytes and synergy with procarbazine in depression of immune responses. Cell Immunol (1973) 1.15
The lymphocytotoxic reaction: the mechanism of rabbit complement action. J Immunol (1971) 1.15
The monoclonal antibody CR11-351 discriminates HLA-A2 variants identified by T cells. Immunogenetics (1983) 1.15
Tumor escape mechanisms: potential role of soluble HLA antigens and NK cells activating ligands. Tissue Antigens (2008) 1.13
Differential tissue distribution and ontogeny of DC-1 and HLA-DR antigens. Immunogenetics (1984) 1.12
Expression of HL-A antigens in synchronized cultures of human lymphocytes. J Immunol (1972) 1.12
Factors influencing recurrent rheumatic fever. Annu Rev Med (1967) 1.11
Lack of HLA class I antigen expression by melanoma cells SK-MEL-33 caused by a reading frameshift in beta 2-microglobulin messenger RNA. J Clin Invest (1993) 1.11
Detection of soluble HLA-G molecules in plasma and amniotic fluid. Tissue Antigens (1999) 1.11
Structural and functional analysis of monomorphic determinants recognized by monoclonal antibodies reacting with the HLA class I alpha 3 domain. J Immunol (1992) 1.10
Expression of HLA class I antigens on hepatocytes in liver disease. Am J Pathol (1986) 1.10
High Staphylococcus aureus nasal carriage rate in patients with acquired immunodeficiency syndrome or AIDS-related complex. Am J Infect Control (1990) 1.09
Cell cycle and the differential expression of HLA-A,B and HLA-DR antigens on human B lymphoid cells. Proc Natl Acad Sci U S A (1980) 1.09
Mutation analysis of BRAF and KIT in circulating melanoma cells at the single cell level. Br J Cancer (2012) 1.07
A simple microabsorption technique for HL-A typing. Proc Soc Exp Biol Med (1972) 1.07
Natural variation of the expression of HLA and endogenous antigen modulates CTL recognition in an in vitro melanoma model. Int J Cancer (1999) 1.07
Is downregulation of MHC class I antigen expression in human non-small cell lung cancer associated with prolonged survival? Cancer Immunol Immunother (2005) 1.07
Soluble human leukocyte antigen--G serum level is elevated in melanoma patients and is further increased by interferon-alpha immunotherapy. Cancer (2001) 1.06
Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol (1989) 1.06
Auscultation of the heart by machine and by physicians. JAMA (1967) 1.05
Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res (1993) 1.05
Biologic and chemical characterization of HLA antigens in human serum. J Immunol (1977) 1.05
Selective loss of human leukocyte class I allospecificities and staining of melanoma cells by monoclonal antibodies recognizing monomorphic determinants of class I human leukocyte antigens. Cancer Res (1993) 1.04
Heterogeneous distribution of the determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation (1982) 1.03
Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies. Cancer Res (1981) 1.02
Structural properties and tissue distribution of the antigen recognized by the monoclonal antibody 653.40S to human melanoma cells. J Natl Cancer Inst (1981) 1.02
HLA antigens in colorectal tumours--low expression of HLA class I antigens in mucinous colorectal carcinomas. Br J Cancer (1987) 1.02
Signal transduction in lymphocyte activation through crosslinking of HLA class I molecules. Hum Immunol (1989) 1.02